Its an area of active research, with studies being done to support these initial benefits and reveal new ones.
Semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 due to preclinical findings of C-cell tumors in rodents[13]
Tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist, reports injection site reaction rates of approximately 1.7-2.2% in its FDA prescribing information, similar to semaglutide
Studies and regulatory findings include: A 2024 study published in JAMA Ophthalmology by researchers at Massachusetts Eye and Ear and Harvard Medical School found that semaglutide users experienced a significantly higher incidence of NAION than patients prescribed other diabetes or weight-loss medications
Phase 2 data showed the 8mg combined group achieved 22.8% mean weight reduction at 48 weeks, which is only 1.4 percentage points less than the 12mg group
From our point of view, when this whole system becomes altered-whether obesity, genetics or environmental factors act to disrupt its symphony-insulin resistance, steatosis, MetS, and ultimately T2D may develop